CRSP240719P82500
- 12.65
- 0.000.00%
CRISPR Therapeutics Newsroom
Institutional Investors Must Be Pleased After a 8.9% Gain Last Week That Adds to CRISPR Therapeutics AG's (NASDAQ:CRSP) One-year Returns
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
CRISPR Therapeutics (NASDAQ:CRSP) Adds US$359m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 54%
Investing in stocks inevitably means buying into some companies that perform poorly. But long term CRISPR Therapeutics AG (NASDAQ:CRSP) shareholders have had a particularly rough ride in the last
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Ark's Cathie Wood Blasts Big Tech. She Prefers Palantir and These Other Stocks.
Cathie Wood's flagship ARK Innovation exchange-traded fund is 72% below its peak while the S&P 500 is hitting all-time highs.
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fund, ARK Innovation ETF (NYSE:ARKK), despite its recent underperformance.
Here's Why CRISPR Therapeutics AG (CRSP) Gained But Lagged the Market Today
Synthetic Immunology Market Report 2024 With Profiles of ADC Therapeutics, BioNTech, Camena Bioscience, CRISPR Therapeutics, Editas Medicine, Sherlock Biosciences, Synlogic Therapeutics & Synthego
Is CRISPR Therapeutics AG (CRSP) the Best Stock to Buy and Hold for 5 Years?
Crispr Therapeutics Coverage Assumed by Guggenheim at Neutral
Crispr Therapeutics Coverage Assumed by Guggenheim at Neutral
Guggenheim Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating
Guggenheim analyst Debjit Chattopadhyay initiates coverage on $CRISPR Therapeutics(CRSP.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 45.2% and a total average
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 Mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new tr
CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon?
Top Gap Ups and Downs on Monday: AVGO, DELL, SONY and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Crispr Therapeutics Price Target Maintained With a $105.00/Share by Piper Sandler
Crispr Therapeutics Price Target Maintained With a $105.00/Share by Piper Sandler
Express News | Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Maintains $105 Price Target